| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| pralsetinib | epithelial discoidin domain-containing receptor 1 | small molecule | NA | drugbank | Medullary carcinoma of thyroid[MeSHID:C536914] Thyroid carcinoma[MeSHID:D013964] Radioactivity[MeSHID:D011851] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| pralsetinib | fibroblast growth factor receptor 1 | small molecule | NA | drugbank | Medullary carcinoma of thyroid[MeSHID:C536914] Thyroid carcinoma[MeSHID:D013964] Radioactivity[MeSHID:D011851] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| pralsetinib | fibroblast growth factor receptor 2 | small molecule | NA | drugbank | Medullary carcinoma of thyroid[MeSHID:C536914] Thyroid carcinoma[MeSHID:D013964] Radioactivity[MeSHID:D011851] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| pralsetinib | receptor-type tyrosine-protein kinase flt3 | small molecule | NA | drugbank | Medullary carcinoma of thyroid[MeSHID:C536914] Thyroid carcinoma[MeSHID:D013964] Radioactivity[MeSHID:D011851] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| pralsetinib | tyrosine-protein kinase jak1 | small molecule | NA | drugbank | Medullary carcinoma of thyroid[MeSHID:C536914] Thyroid carcinoma[MeSHID:D013964] Radioactivity[MeSHID:D011851] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| pralsetinib | tyrosine-protein kinase jak2 | small molecule | NA | drugbank | Medullary carcinoma of thyroid[MeSHID:C536914] Thyroid carcinoma[MeSHID:D013964] Radioactivity[MeSHID:D011851] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| pralsetinib | vascular endothelial growth factor receptor 2 | small molecule | NA | drugbank , DGIDB | Medullary carcinoma of thyroid[MeSHID:C536914] Thyroid carcinoma[MeSHID:D013964] Radioactivity[MeSHID:D011851] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.23 | approved,investigational | inhibitor |
| pralsetinib | high affinity nerve growth factor receptor | small molecule | NA | drugbank | Medullary carcinoma of thyroid[MeSHID:C536914] Thyroid carcinoma[MeSHID:D013964] Radioactivity[MeSHID:D011851] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| pralsetinib | nt-3 growth factor receptor | small molecule | NA | drugbank | Medullary carcinoma of thyroid[MeSHID:C536914] Thyroid carcinoma[MeSHID:D013964] Radioactivity[MeSHID:D011851] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| pralsetinib | platelet-derived growth factor receptor beta | small molecule | NA | drugbank | Medullary carcinoma of thyroid[MeSHID:C536914] Thyroid carcinoma[MeSHID:D013964] Radioactivity[MeSHID:D011851] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,investigational | inhibitor |
| pralsetinib | proto-oncogene c-ret | NA | Successful target | TTD , DGIDB | Medullary carcinoma of thyroid[MeSHID:C536914] Thyroid carcinoma[MeSHID:D013964] Radioactivity[MeSHID:D011851] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
1.43 | approved | inhibitor |
| pralsetinib | proto-oncogene tyrosine-protein kinase receptor ret | small molecule | NA | drugbank , DGIDB | Medullary carcinoma of thyroid[MeSHID:C536914] Thyroid carcinoma[MeSHID:D013964] Radioactivity[MeSHID:D011851] Non-Small Cell Lung Carcinoma[MeSHID:D002289] Malignant Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
1.43 | approved,investigational | inhibitor |
| click here to return to the previous page | ||||||||